Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis.
Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis.
复制标题
DOI：
10.1007/s40120-021-00319-3
复制
发表时间：
2022-03
影响因子：
3.7
通讯作者：
Bonine NG
中科院分区：
文献类型：
--
作者：
Pardo G;Pineda ED;Ng CD;Bawa KK;Sheinson D;Bonine NG
我们试图通过给药途径（罗阿）评估ocrelizumab（OCR）与其他疾病修饰治疗（DMT）相比在美国治疗多发性硬化症（MS）24个月后的依从性和持久性。这项对启动新DMT的MS患者的回顾性索赔分析是在2016年4月至2019年12月期间使用IBM MarketScan Commercial和Medicare Supplemental数据库进行的。要求在开始索引DMT之前连续入组≥ 12个月，并且在开始索引DMT之后持续入组24个月。根据随访期间覆盖天数比例（PDC）评估依从性，其中≥ 80%的数值视为依从性。持续性定义为没有证据表明转换为另一种DMT或DMT覆盖率无≥ 60天的间隔。共纳入1710例随访≥ 24个月的患者（OCR，n = 524;口服，n = 701;注射，n = 365;其他静脉[IV]，n = 120）。开始OCR的患者在24个月时具有更高的依从性（口服、注射和其他IV分别为80% vs. 55%、35%和54%）和持久性（分别为75% vs. 54%、33%和55%）。与开始OCR的患者相比，开始口服、注射和其他IV的患者24个月不依从的相对风险（RR）分别为2.2（95% CI，1.7-2.9）、3.0（95% CI，2.2-4.0）和2.2（95% CI，1.5-3.3）。同样，接受口服、注射和其他IV治疗的患者停药24个月的RR分别为1.9（95% CI，1.4-2.4）、2.5（95% CI，1.9-3.4）和1.8（95% CI，1.2-2.6）。在12个月和18个月时观察到相似的模式。在真实世界环境中开始OCR的患者在24个月时的依从性和持续性高于开始其他DMT的患者，与已发表的文献一致，显示在12个月和18个月时的结果相似。优化药物依从性和持久性是MS护理的基础，因此临床医生应考虑可能提高依从性的DMT的所有要素。在线版本包含补充材料，可通过10.1007/s40120-021-00319-3获得。
We sought to assess adherence to and persistence with ocrelizumab (OCR) compared with other disease-modifying treatments (DMTs), by route of administration (RoA), for multiple sclerosis (MS) after 24 months in the United States. This retrospective claims analysis of MS patients initiating a new DMT was conducted using the IBM MarketScan Commercial and Medicare Supplemental databases between April 2016 and December 2019. Continuous enrollment of ≥ 12 months before and up to 24 months after initiating the index DMT was required. Adherence was assessed based on proportion of days covered (PDC) in the follow-up period with values ≥ 80% considered adherent. Persistence was defined as no evidence of switching to another DMT or no gap ≥ 60 days in DMT coverage. A total of 1710 patients with ≥ 24 months of follow-up (OCR, n = 524; oral, n = 701; injectable, n = 365; other intravenous [IV], n = 120) were included. Patients initiating OCR had higher adherence (80% vs. 55%, 35%, and 54% for oral, injectable, and other IV, respectively) and persistence (75% vs. 54%, 33%, and 55%, respectively) at 24 months. Relative risks (RRs) of 24-month non-adherence for those initiating orals, injectables, and other IVs were 2.2 (95% CI, 1.7–2.9), 3.0 (95% CI, 2.2–4.0), and 2.2 (95% CI, 1.5–3.3), respectively, compared to those initiating OCR. Similarly, patients receiving orals, injectables, and other IVs had RR of 1.9 (95% CI, 1.4–2.4), 2.5 (95% CI, 1.9–3.4), and 1.8 (95% CI, 1.2–2.6) for 24-month discontinuation, respectively. Similar patterns were observed at 12 and 18 months. Patients initiating OCR in a real-world setting achieved higher rates of adherence and persistence at 24 months compared with those initiating other DMTs, consistent with published literature showing similar results at 12 and 18 months. Optimizing medication adherence and persistence is fundamental to MS care, so clinicians should consider all elements of DMTs that may improve compliance. The online version contains supplementary material available at 10.1007/s40120-021-00319-3.
登录
查看更多内容
影响因子：
5.3
作者：
Fernandez-Diaz E;Perez-Vicente JA;Villaverde-Gonzalez R;Berenguer-Ruiz L;Candeliere Merlicco A;Martinez-Navarro ML;Gracia Gil J;Romero-Sanchez CM;Alfaro-Saez A;Diaz I;Gimenez-Martinez J;Mendez-Miralles MA;Millan-Pascual J;Jimenez-Pancho J;Mola S;Sempere AP
通讯作者：
Sempere AP
影响因子：
5.1
作者：
Devonshire, V.;Lapierre, Y.;Kieseier, B. C.
通讯作者：
Kieseier, B. C.
DOI：
10.18553/jmcp.2016.22.12.1394
发表时间：
2016-12-01
影响因子：
2.1
作者：
Higuera, Lucas;Carlin, Caroline S.;Anderson, Sarah
通讯作者：
Anderson, Sarah
影响因子：
2.9
作者：
Gil-González I;Martín-Rodríguez A;Conrad R;Pérez-San-Gregorio MÁ
通讯作者：
Pérez-San-Gregorio MÁ
影响因子：
2.1
作者：
Johnson, Kristen M;Zhou, Huanxue;Herrera, Vivian
通讯作者：
Herrera, Vivian